HHS Secretary Robert F. Kennedy Jr. has halted mRNA funding in the U.S., declaring these jabs “extremely dangerous” based on a comprehensive review of their risks, winding down related activities under the Biomedical Advanced Research and Development Authority (BARDA) to prioritize safer vaccine development.
This major shift follows an in-depth evaluation of investments initiated during the COVID-19 emergency, where RFK Jr. emphasized reliance on scientific data and expert recommendations to guide the decision. By redirecting resources away from mRNA technologies, the HHS aims to address ongoing concerns about efficacy, long-term side effects, and public trust, marking a pivotal change in national health priorities under the Trump administration.
Thegatewaypundit.com reports: BARDA is terminating twenty-two mRNA vaccine projects worth nearly $500 million, as these vaccines have shown limitations in protecting against upper respiratory infections like COVID-19 and flu.
BYPASS THE CENSORS
Sign up to get unfiltered news delivered straight to your inbox.
You can unsubscribe any time. By subscribing you agree to our Terms of Use
The department is moving beyond mRNA’s constraints to invest in better solutions that mimic natural immunity. Traditional methods like whole-virus vaccines offer proven durability, unlike mRNA’s rapid but mutation-sensitive design.
Justin Trudeau and Katy Perry Exposed Dining on Raw 'Child Flesh' in Paris
Funding will now redirect toward safer, more effective platforms that hold up against viral mutations. This includes whole-virus vaccines and novel technologies with stronger safety records and transparent data practices.
“We reviewed the science, listened to the experts, and acted,” said Secretary Kennedy. He continued that HHS fully supports safe, effective vaccines for all Americans who choose them.
Kennedy reiterated his commitment to informed choice, stating during his confirmation that he is neither anti-vaccine nor anti-industry. He aims to ensure vaccines meet high standards of efficacy and safety.
Specific actions include terminating contracts with Emory University and Tiba Biotech for mRNA platforms. De-scoping affects existing deals with Luminary Labs, ModeX, and Seqirus.
Collaborations with the Department of Defense are being restructured, impacting nucleic acid-based projects with AAHI, AstraZeneca, HDT Bio, and Moderna/UTMB.
Multiple pre-award solicitations are being rejected or canceled, including proposals from Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and others under BARDA’s Rapid Response Partnership Vehicle and VITAL Hub.
Some final-stage contracts, like those with Arcturus and Amplitude, will complete to honor prior taxpayer investments.
HHS notes that other departmental uses of mRNA, such as in cancer research, remain unaffected.
No new mRNA-based initiatives will start, and BARDA Ventures will halt equity investments in mRNA through the Global Health Investment Corporation.
This policy aligns with the Trump administration’s focus on evidence-based health strategies that prioritize American well-being.
Experts within the administration see this as strengthening national biosecurity by favoring reliable technologies.
Kennedy’s leadership reflects a MAGA-era emphasis on practical, people-first policies. He vowed post-election not to remove vaccines but to enhance information and option and this wind-down represents a bold step toward safer vaccine development.
